ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

XR Tacrolimus Dosing By Ideal Body Weight Reduces Incidence Of Early Supratherapeutic Tacrolimus Concentrations

G. Codispodo, J. Hedvat, D. Salerno, N. Lange

Pharmacy, NewYork-Presbyterian Hospital, New York, NY

Meeting: 2022 American Transplant Congress

Abstract number: 9089

Keywords: Dosage, Kidney transplantation, Weight

Topic: Clinical Science » Kidney » 38 - Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Information

Session Name: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Abstract

Date: Tuesday, June 7, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: At our center, the use of de novo Envarsus XR® (extended-release [XR] tacrolimus) dosed at 0.12 mg/kg is standard of care in adult kidney transplant recipients (KTR). Based on a center-specific analysis, our center adopted a protocol change in weight-based dosing of XR tacrolimus from actual body weight (ABW) to ideal body weight (IBW). The purpose of this study was to compare the incidence of early supratherapeutic tacrolimus levels in the different weight-based cohorts.

*Methods: This was an IRB-approved, single center retrospective analysis of adults who received a KT between 07/2019-1/2021. Patients were excluded if they received medications that interact with tacrolimus or if they received different formulations of tacrolimus during the first 2 weeks post-KT. Due to associations between increasing age and increased risk of supratherapeutic tacrolimus levels, patients were matched 1:1 by age using nearest neighbor methodology. The primary endpoint was the difference in early supratherapeutic levels between the pre and post implementation of IBW dosing cohorts, defined as 1 appropriately timed tacrolimus trough greater than 12 ng/mL between postoperative day (POD) 2-4. Secondary endpoints included incidence of subtherapeutic levels < 6.0 ng/mL and < 4.0 ng/mL at any point between POD 5-14.

*Results: A total of 208 kidney transplant recipients (KTR) were identified. After 1:1 matching on age, 114 KTR were included in the analysis; 57 in each group respectively. KTR in the pre-cohort and post-cohort weighed 73.6 kg (IQR, 62.9 – 87.2) and 78.0 kg (IQR, 70.3 – 88.9) with IBW of 63.2 kg (IQR, 54.6 – 73.0) and 63.8 kg (IQR, 52.0 – 73.0), respectively. Median XR tacrolimus doses on POD1 were 9 mg (IQR, 8 – 10) in the pre-cohort and 8 mg (IQR, 7 – 9) in the post-cohort. Overall, the incidence of supratherapeutic concentrations was 42.1% in the pre-cohort vs. 19.3% in the post-cohort (p<0.008). Subtherapeutic levels were not statistically different between groups with the incidence of concentrations < 6.0 ng/mL observed in 40.4% vs. 43.9% (p=0.704) and < 4.0 ng/mL observed in 14.0% vs. 12.3% (p=0.782) of KTR, in the pre- and post-cohorts respectively. IBW dosing was associated with avoidance of early supratherapeutic tacrolimus concentrations aOR 0.3 (95%CI, 0.2 - 0.72; p=0.007).

*Conclusions: XR tacrolimus dosed empirically by IBW results in significantly less initial supratherapeutic levels with comparable subtherapeutic levels when compared with ABW dosing.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Codispodo G, Hedvat J, Salerno D, Lange N. XR Tacrolimus Dosing By Ideal Body Weight Reduces Incidence Of Early Supratherapeutic Tacrolimus Concentrations [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/xr-tacrolimus-dosing-by-ideal-body-weight-reduces-incidence-of-early-supratherapeutic-tacrolimus-concentrations/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences